Back

Protease-activated receptor 2 (PAR2) inhibition reduces complement-associated cardiac remodelling in obesity-related heart failure

1 September 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Obesity and heart failure: what's new? Ventricular Remodelling ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Emily Ghanbari

German Heart Centre Berlin, Berlin (Germany)

7 More presentations in this session

Presentation thumbnail
In-hospital economic impact and mortality of bariatric surgery on congestive heart failure in the USA: a nationwide analysis
Doctor S. Sinclair (Yankton, US)
Abstract Slides Video
Presentation thumbnail
What characterizes normotensive individuals with obesity and normal systolic heart function? A descriptive study from the SCAPIS cohort
Doctor J. Korduner (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Effects of body mass index on worsening of heart failure and all-cause death in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study
Mr M. Malmborg (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Association of epicardial adipose tissue with cardiac geometry alternation and diastolic dysfunction in the early stage of diabetic cardiomyopathy
Doctor J. Hsu (New Taipei City, TW)
Abstract Slides Video
Presentation thumbnail
Effect of empagliflozin on epicardial adipose tissue volume in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
Ms C. Turgut (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and heart failure: what's new?

The Event

Event poster

ESC Congress 2024

1 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Investigating the role of protease-activated receptor 2 in adverse cardiac remodeling and clinical outcomes in heart failure: insights from translational research
thumbnail
Congress Session
Basic and Translational Late-Breaking Science session
thumbnail
Congress Presentation
Inflammatory and adipokine-associated proteomic signatures of heart failure progression by body mass index: insights from the EXAMINE trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources